What is the appropriate treatment for sacroiliac joint arthritis?

Treatment of Sacroiliac Joint Arthritis

For sacroiliac joint arthritis in the context of axial spondyloarthritis, start with continuous NSAIDs as first-line pharmacological treatment, and if inadequate response occurs after trying at least two NSAIDs, escalate to biologic DMARDs (TNF inhibitors or IL-17 inhibitors) rather than conventional DMARDs. 1, 2

Initial Pharmacological Management

NSAIDs represent the cornerstone of initial treatment for active sacroiliac joint arthritis:

• Start with continuous NSAID therapy rather than on-demand dosing for active disease 1
• No specific NSAID is preferred over another—choose based on patient tolerance and comorbidities 1
• Once disease is stable, switch to on-demand NSAID use 1

Role of Local Corticosteroid Injections

For patients with isolated active sacroiliitis despite NSAID treatment:

• Image-guided intra-articular corticosteroid injections are conditionally recommended 1
• Use fluoroscopic or CT guidance for accurate placement—image guidance produces superior outcomes compared to landmark-based injections 3
• Expect significant pain reduction in the short-term (VAS dropping from 8.2 to 3.2), though efficacy diminishes over time with VAS returning to 5.1 at longer follow-up 4
• Approximately 13% of patients will not respond to steroid injections 4

Critical caveat: Long-term systemic glucocorticoids are strongly recommended AGAINST for axial disease 1

When to Escalate to Biologic Therapy

Escalate to biologic DMARDs when:

• Inadequate response to at least two different NSAIDs (tried at adequate doses)
• High disease activity persists
• Patient has elevated CRP and/or definite inflammation on MRI and/or radiographic sacroiliitis 2

Biologic DMARD selection:

• Start with either a TNF inhibitor or IL-17 inhibitor—both are strongly recommended as first-line biologics 1
• Current practice typically begins with TNF inhibitors 2
• If the first biologic fails (primary failure), switch to a different mechanism of action (e.g., TNF inhibitor to IL-17 inhibitor or vice versa) 1
• JAK inhibitors are strongly recommended when biologics are contraindicated or unavailable 1

What NOT to Use

Avoid these treatments for purely axial involvement:

• Sulfasalazine, methotrexate, or leflunomide have no role in isolated axial disease 1
• These conventional DMARDs only have utility if active peripheral arthritis is present 1

Interventional Options for Refractory Cases

For patients failing conservative management, radiofrequency ablation techniques show effectiveness:

• Cooled RF ranks highest at 1 month, conventional RF at 3 months, and pulsed RF at 6 months for pain relief 5
• RF-based interventions consistently outperform steroid injections and conservative care 5
• Consider these before proceeding to surgical fusion 6, 7

Treatment Monitoring

Use a target-based strategy with:

• ASDAS (Ankylosing Spondylitis Disease Activity Score) and/or SASDAS scores 1
• Aim for low disease activity or remission
• Lower disease activity correlates with less radiographic progression 1

Common Pitfalls to Avoid

1. Don't use conventional DMARDs for isolated axial disease—they are ineffective and delay appropriate biologic therapy 1
2. Don't perform landmark-guided injections—always use imaging guidance for sacroiliac joint injections 3
3. Don't continue NSAIDs indefinitely once remission is achieved with biologics—discontinue NSAIDs when stable on biologic therapy 1
4. Don't combine biologics with conventional DMARDs in remission—this combination is strongly recommended against 1